Risks
4 risks
Risk Intelligence
Product mix deterioration in acute season
View Risks →Alkem Laboratories Limited — Q1 FY25
Alkem Laboratories reported a strong Q1 FY25 with EBITDA margin expanding 700 bps YoY to 20.1%, driven by favorable API pricing, improved product mix, and cost controls.
bullish
high
Financial stats pending filing verification
2-Minute Summary
✦ AI-Generated from Full Transcript
Alkem Laboratories reported a strong Q1 FY25 with EBITDA margin expanding 700 bps YoY to 20.1%, driven by favorable API pricing, improved product mix, and cost controls. Net profit stood at INR 545 crore. Domestic business grew in line with IPM at 8.4%, with chronic therapies outperforming. US business saw single-digit price erosion but new launches (Suprac, Dabigatran) are expected to contribute from H2. Management maintained full-year EBITDA margin guidance of ~18%, as investments in Enzene CDMO and medical devices will offset gross margin gains of ~150 bps. Key risk: slower-than-expected ramp-up of new US launches or adverse product mix in acute season quarters.
अल्केम लैबोरेटरीज ने पहली तिमाही (Q1 FY25) में शानदार प्रदर्शन किया। कंपनी का EBITDA मार्जिन (कमाई का वह हिस्सा जो खर्च निकालने के बाद बचता है) पिछले साल की तुलना में 7% बढ़कर 20.1% हो गया। इसकी वजह है कच्चे माल की सस्ती कीमत, बेहतर उत्पाद मिश्रण और खर्च पर नियंत्रण। कंपनी का शुद्ध लाभ 545 करोड़ रुपये रहा। भारत में बिक्री 8.4% बढ़ी, जिसमें पुरानी बीमारियों की दवाओं ने अच्छा प्रदर्शन किया। अमेरिका में कीमतों में थोड़ी गिरावट आई, लेकिन नई दवाएं (Suprac, Dabigatran) साल की दूसरी छमाही से मुनाफा देंगी। कंपनी ने पूरे साल के लिए EBITDA मार्जिन 18% रहने का अनुमान लगाया है। जोखिम: नई अमेरिकी दवाओं की बिक्री धीमी रह सकती है या मौसमी बीमारियों के मौसम में उत्पाद मिश्रण खराब हो सकता है।
Risks4 trackedTranscriptfull text
Research workspace
Focused Modules
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
EBITDA Margin
20.1%
+700 bps YoY
Improved from 13.1% in Q1 FY24, driven by API pricing and cost controls.
Domestic Volume Growth
1.5%
+1.5% YoY
Volume growth in domestic formulation segment for Q1 FY25.
Gross Margin Guidance
62.5%
+150 bps YoY
Full-year gross margin expected to improve to 62.5% from 61% last year.
Medical Representative Count
12,700
flat
Current MR count for India business, excluding managers.
What Changed vs Last Quarter
NEW
Full-year EBITDA margin around 18%
Management expects EBITDA margin for FY25 to be around 18%, similar to last year, despite gross margin improvement, due to investments in new growth initiatives.
NEW
Gross margin improvement of ~150 bps to 62.5%
Full-year gross margin expected to improve to 62.5% from 61% in FY24, driven by favorable API pricing and product mix.
NEW
Domestic business growth in line with IPM (8-10%)
India business expected to grow in line with the Indian pharmaceutical market, which is projected at 8-10%.
NEW
US business single-digit growth with new launches
US business expected to see single-digit growth, with Dabigatran contributing meaningfully from Q3/Q4.
DROPPED
FY25 Revenue Growth ~10%
Management expects overall revenue growth of around 10% in FY25, driven by domestic volume growth and stable US business.
DROPPED
EBITDA Margin to Remain at Current Levels
EBITDA margin expected to be in line with FY24 levels (~17.7%), with potential 20-30 bps improvement but offset by investments.
DROPPED
CapEx of INR 600-700 Cr in FY25
Total CapEx for FY25 is guided at INR 600-700 crore, including ~INR 400 crore for the US CDMO facility and INR 80-100 crore maintenance.
DROPPED
R&D Spend to Rise to 4.5-5%
R&D expenditure is expected to increase from 4.1% in FY24 to 4.5-5% of revenue in FY25, driven by biosimilar clinical trials.
NEW RISK
Product mix deterioration in acute season
Q2 and Q3 typically see higher anti-infective sales, which could lower margins by ~2% due to product mix shift.
NEW RISK
Investment drag from Enzene and medical devices
New initiatives (CDMO, medical devices) will incur losses and impact EBITDA by ~0.5 ppt in H2, with breakeven expected only by FY26.
NEW RISK
US price erosion and launch delays
US generic business faces single-digit price erosion; new product ramp-up may be slower than expected, limiting revenue contribution.
NEW RISK
Mirabegron launch uncertainty
Launch of Mirabegron is tied to litigation outcomes and settlement agreement, with earliest possible entry in 2026-27, limiting near-term US upside.
RISK GONE
Sluggish Anti-Infective Season
Q4 domestic decline was partly due to a weak anti-infective season; if FY25 monsoon is poor, acute portfolio growth may underperform.
RISK GONE
Raw Material Cost Inflation
While API prices are stable, any black swan event could increase costs; Pen G price decline has not materialized as expected.
RISK GONE
US Supply Chain Penalties
Q4 had INR 30 crore in service-level penalties due to supply issues; if not resolved, could impact US margins.
RISK GONE
Baddi Site FDA Observations
Baddi site received 10 observations from US FDA; though management downplayed, any escalation could delay approvals.
🤫 Topics management stopped discussing
Mentioned in Q2 FY24, Q4 FY24
Q4 had INR 30 crore in service-level penalties due to supply issues; if not resolved, could impact US margins.
Mentioned in Q2 FY24, Q3 FY24
Management expects FY24 EBITDA margin around 17%, with Q4 seasonally weaker but sustainable at that level.
Fast read
Guidance and risk preview
Management expects EBITDA margin for FY25 to be around 18%, similar to last year, despite gross margin improvement, due to investments in new growt...
Q2 and Q3 typically see higher anti-infective sales, which could lower margins by ~2% due to product mix shift.
View Risks →